Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Biotech-Wars™ Counteroffensive

|About: Johnson & Johnson (JNJ)
Summary

politicos have made a massive mistake vilifying the biotech sector.

politicos continue to see the biotech sector as easy targets in an effort to gain votes and win elections.

It is time for all biotech companies to take counteroffensive measures.

Biotech-Wars™ Counteroffensive-fighting back

The healthcare debate is not winnable for any political candidate as it is highly complicated and involves significant costs no matter which way one goes. Based on the last Democratic political debate I think that the Affordable Care Act program should be re-worked vs. introducing an expensive Medicare for all program. Medicare could be revised to cover the 60-64 age group if this is affordable.

Predictably the www.biotech-wars.com will continue for a long time, especially when you add in all the current opioid litigations. And politicos continue to see the biotech sector as easy targets in an effort to gain votes and win elections.

There is no doubt that Johnson & Johnson remains the biggest target for lawyers and politicos. Below is an assessment of Johnson & Johnson’s situation from one of the people I follow on Seeking Alpha - Out of Ignorance the article paints a very bleak picture for (JNJ). Basically, the writer is concluding that Johnson & Johnson will be a legal target for many years and also writes “JNJ can expect bad headlines in abundance as the years unfold”. And I do agree with the writer’s comment “My prognosis for JNJ shareholders is prolonged discomfort.” I think this comment would apply to all biotech investments.

Johnson & Johnson's Dead Serious Opioid Issues

It is time for all biotech companies, and not just for (JNJ), to take counteroffensive measures.

It remains my view that politicos have made a massive mistake vilifying the biotech sector. There could be significant R&D/product development shifts away from America based on the anti-biotech sentiment that currently exists.

Unfortunately, I also see that the Biotech-Wars™ are now expanding towards both Tech-Wars and Class-Wars as politicos see additional voting gains attacking larger highly successful tech companies, especially Google, Facebook, Amazon, and Apple and wealthy Americans. The political vilification of successful American tech companies and wealthy Americans is troubling.

Billionaire investor Carl Icahn to leave New York for Florida

In the face of all of this negative political commentary, biotech companies continue to make remarkable success with new products and new meds. Below are articles from just a few days in September 2019 highlighting noteworthy biotech news and achievements;

FDA Accepts Merck's Biologics License Application (BLA) and Grants Priority Review for V920, the Company's Investigational Vaccine for Ebola Zaire Virus

Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the European Society for Medical Oncology (ESMO) 2019 Congress

Galectin Therapeutics and Providence Cancer Institute nab new patent in U.S.

Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index

Regeneron Debuts on Prestigious Dow Jones Sustainability World Index of Most Sustainable Companies

CRISPR Therapeutics and ViaCyte Present Positive In Vitro Data Towards a Potential Immune-Evasive Cell Replacement Therapy for Diabetes at EASD 2019

Medtronic Introduces Envision™ Pro Continuous Glucose Monitoring (CGM) System in Europe

GW Pharmaceuticals (NASDAQ:GWPH) Investor Presentation - Slideshow

Sesen Bio (NASDAQ:SESN) Presents At H.C. Wainwright 21st Annual Global Investment Conference - Slideshow

CytoDyn (OTCQB:CYDY) Investor Presentation - Slideshow

Abbott Named the Industry Leader in Sustainability for the Seventh Consecutive Year on the Dow Jones Sustainability Index (DJSI)

Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer

Varian Announces Multi-room Configuration for ProBeam 360 Proton Therapy System

National Lipid Association's New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognizes Importance of Addressing Residual Cardiovascular Risk in Patients on Statins

Medtronic and Novo Nordisk Enter Agreement to Provide Integrated Digital Solutions for People with Diabetes

FDA grants Fast Track designation for Farxiga in heart failure

Keytruda/Lenvima combo simultaneously OK'd in U.S., Australia and Canada

FDA Approves KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma

FDA Grants Breakthrough Therapy Designation for Genentech's Gazyva (Obinutuzumab) in Lupus Nephritis

Amgen Inc. (NASDAQ:AMGN) Management Presents at The Bank of America Merrill Lynch Global Healthcare Conference (Transcript)

Amgen Showcases New Data From Oncology Pipeline And Portfolio At ESMO 2019

 Biogen Advances Spinal Muscular Atrophy (NYSE:SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients

bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (NASDAQ:CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress

Healthy Dividends: Finding Refuge In Bristol-Myers Squibb

In a year that the biotech sector has been totally maligned by politicos, biotech companies will again achieve outstanding medical success as they did in 2018. I remain 100% invested in biotech and medtech companies as of 9/18/2019. And I remain long (JNJ). 

Respectfully submitted to Seeking Alpha on 9/18/2019.

Dan Watson

Seeking Biotech Alpha

home | Dan Watson

Disclosure: I am/we are long ABBV, AZN, AMGN, BMY, PFE, MRK, LLY, CELG, MDT, RHHBY, JNJ.